[Persistent injecting practices in subjects on methadone or buprenorphine maintenance therapy. A study of 600 cases].

Ann Med Interne (Paris)

Psychiatre des Hôpitaux, Praticien Hospitalier, CH d'Erstein, 13, route de Krafft, 67152 Erstein.

Published: November 2001

A descriptive study conducted at the Louis-Harris Institute enrolled 600 patients taking methadone or buprenorphine (Subutex((R))) substitution therapy who were followed by general practitioners or specialists working in specialized clinics. The objective was to look for factors correlated with persistent injecting practices. Several factors were found to be statistically correlated with persistent injecting practices: impulsiveness, depressive state, and relative under-dosing (first daily or globally) in patients on Subutex((R)). Considering these factors, a better psychosocial impact could be achieved by providing sufficient attention to anxious or depressive states aggravating the effects of impulsiveness (co-usage of certain substances, psychotonics, search for certain psychopathological states) and paying special attention to the more impulsive subjects. Optimal coverage with earlier orientation to appropriate psychiatric care requires a team effort including educators, social workers and healthcare professionals. Such measures must be conducted within the framework of good clinical practices to establish a coherent multidisciplinary healthcare scheme which should help eliminate this source of more or less overt somatic complications. Such good clinical practice could also facilitate safe extinction of the conditioning inferred by addicted behavior (persistent injecting practices) which could persist only a few months after the end of the stimulus (cessation of emotional pain).

Download full-text PDF

Source

Publication Analysis

Top Keywords

injecting practices
16
persistent injecting
12
methadone buprenorphine
8
correlated persistent
8
good clinical
8
practices
5
[persistent injecting
4
practices subjects
4
subjects methadone
4
buprenorphine maintenance
4

Similar Publications

Article Synopsis
  • CAB + RPV is the first long-acting HIV treatment regimen using thigh injections, showing promising results in maintaining viral suppression.
  • The study involved 118 participants and compared pharmacokinetic changes and tolerability between thigh and gluteal injections, finding no significant differences in effectiveness.
  • Results indicated that a majority of participants preferred thigh injections, with potential plans for more flexible dosing schedules to enhance treatment convenience.
View Article and Find Full Text PDF

Although idiopathic granulomatous mastitis (GM) of the breast is a benign condition, it can be locally aggressive and frequently chronic, causing significant pain and distress to the patient. Treatment often involves multiple disciplines including general practice, breast surgery/physicians, rheumatology and/or immunology. Traditional options for treatment include observation, oral steroids, methotrexate and/or surgery, all with variable outcomes.

View Article and Find Full Text PDF

Horses of different ages may have to be killed on-farm for purposes other than slaughter (where slaughter is defined as killing for human consumption) either individually (i.e. on-farm killing of unproductive, injured or terminally ill animals) or on a large-scale (i.

View Article and Find Full Text PDF

Versatile hydrogels prepared by microfluidics technology for bone tissue engineering applications.

J Mater Chem B

January 2025

State Key Laboratory of Oral Disease & National Center for Stomatology & National Clinical Center for Oral Diseases & Department of Operative Dentistry and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.

Bone defects are a prevalent issue resulting from various factors, such as trauma, degenerative diseases, congenital disabilities, and the surgical removal of tumors. Current methods for bone regeneration have limitations. In this context, the fusion of tissue engineering and microfluidics has emerged as a promising strategy in the field of bone regeneration.

View Article and Find Full Text PDF

Background: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their LDL-C target. Recently, a 2-mL prefilled autoinjector has been developed to support the monthly 300-mg dosing regimen with a single-injection administration.

Methods And Objectives: Monthly application of 300 mg AlirRocumab (Praluent) using the 2-mL SYDNEY Device (MARS) is a non-interventional, open, prospective, multi-center cohort study conducted in Germany between 2021 and 2023 with an observational period of 12 weeks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!